BioSpace News Archive

Business

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

May 1, 2023
·
1 min read
Business

Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023.

May 1, 2023
·
1 min read
Business

Galera Expands Commercial Leadership Team

Galera Therapeutics, Inc. today announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately.

May 1, 2023
·
11 min read
Business

Alladapt Appoints Louise Peacock as Chief Regulatory Affairs and Quality Officer

Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced the appointment of Louise Peacock as Chief Regulatory Affairs and Quality Officer, effective May 1, 2023.

May 1, 2023
·
3 min read
Genetown

Werewolf Therapeutics to Participate in May Investor Conferences

Werewolf Therapeutics, Inc. today announced that management will participate at the following conferences in the month of May.

May 1, 2023
·
1 min read
Genetown

Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FDA grants appeal and files NDA

Minerva Neurosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia on April 27, 2023.

May 1, 2023
·
5 min read
Pharm Country

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

Axsome Therapeutics, Inc. is joining Mental Health America (MHA) and the State of New York to raise awareness of mental health during May is Mental Health Month.

May 1, 2023
·
7 min read
FDA

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

Cabaletta Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy.

May 1, 2023
·
8 min read
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism.

May 1, 2023
·
6 min read
Biotech Beach

Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials

Eledon Pharmaceuticals, Inc. today announced that it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $185 million in gross proceeds to Eledon through a private placement.

May 1, 2023
·
6 min read